Personalis (NASDAQ:PSNL) vs. Seer (NASDAQ:SEER) Head-To-Head Contrast

Personalis (NASDAQ:PSNL) and Seer (NASDAQ:SEER) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Risk & Volatility

Personalis has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.

Earnings & Valuation

This table compares Personalis and Seer”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.67 million	23.82	-$81.27 million	($1.09)	-14.54
Seer	$16.58 million	6.58	-$73.60 million	($1.22)	-1.61

Seer has lower revenue, but higher earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Personalis and Seer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Seer	-478.05%	-27.23%	-23.99%

Institutional and Insider Ownership

61.9% of Personalis shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 4.2% of Personalis shares are owned by company insiders. Comparatively, 11.3% of Seer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Personalis and Seer, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1	7	3	0	2.18
Seer	1	0	0	2	3.00

Personalis currently has a consensus price target of $14.54, suggesting a potential downside of 8.29%. Seer has a consensus price target of $4.00, suggesting a potential upside of 103.05%. Given Seer’s stronger consensus rating and higher probable upside, analysts plainly believe Seer is more favorable than Personalis.

Summary

Seer beats Personalis on 9 of the 15 factors compared between the two stocks.

About Personalis

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.